Eradia 125 mg/ml, oral suspension for dogs

Authorised

- Metronidazole

Product identification

Medicine name:
Eradia 125 mg/ml, oral suspension for dogs
Eradia 125 mg/ml suspensija iekšķīgai lietošanai suņiem

Active substance:
Metronidazole

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Metronidazole
125.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral suspension

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01XD01
QP51AA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Latvia

Available in:
Latvia

Package description:
100 ml presentation: white opaque polyethylene terephthalate (PET) bottle equipped with a sampling polypropylene (PP) snap cap with silicon stopper and a 3 ml polypropylene (PP) syringe placed in a carton box
30 ml presentation: white opaque polyethylene terephthalate (PET) bottle equipped with a sampling polyethylene (PE) screw cap with PE seal and a 3 ml polypropylene (PP) oral syringe placed in a carton box
100 ml presentation: white opaque polyethylene terephthalates (PET) bottle equipped with a sampling Polyethylene (PE) screw cap with PE seal and a 3 ml polypropylene (PP) oral syringe placed in a carton box
30 ml presentation: white opaque polyethylene terephthalate (PET) bottle equipped with a sampling polypropylene (PP) snap cap with silicon stopper and a 3 ml polypropylene (PP) syringe placed in a carton box

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
2/03/2018

Manufacturing sites for batch release:
Delpharm Huningue S.A.S.
Virbac S.A.

Responsible authority:
Food And Veterinary Service

Authorisation number:
V/DCP/18/0007

Date of authorisation status change:
2/03/2018

Reference member state:
Netherlands

Procedure number:
NL/V/0232/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 9/05/2024
Download

Final PuAR Eradia 125 mg-ml oral suspension for dogs_update 05112023.pdf